跳至主要内容
临床试验/NCT03846206
NCT03846206Unknown不适用

Changes in Bacterial Translocation and Immune Activation in Patients Infected With HIV After Change to a Supplemented Mediterranean Diet: Two Arms Randomized Prospective Trial.

Hospital Clinic of Barcelona2 个研究点 分布在 1 个国家目标入组 102 人开始时间: 2016年7月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
入组人数
102
试验地点
2
主要终点
Differences in levels of sCD14 at baseline and month 3 between groups

研究概览

简要总结

Evaluate if a change to a Mediterranean diet supplemented with nuts and olive oil decreases bacterial translocation and immune activation by a change in the microbiome in successfully treated HIV-1 infected patients with CD4> 500cells/ml.

详细描述

Mediterranean diet supplemented by nuts and extra virgin olive oil has shown to reduce mortality, cardiovascular diseases, and breast cancer in HIV uninfected individuals. It is likely that changes in the microbiome could play a role in this effect. The goal of the study is to evaluate if a change to a Mediterranean diet supplemented with nuts and olive oil decreases bacterial translocation and immune activation by a change in the microbiome in successfully treated HIV-1 infected patients with CD4> 500cells/ml. One hundred and two patients who will be randomized to continues usual diet or to a Mediterranean diet supplemented with 50 g / day of olive oil and 15g / day of nuts for three months. Throughout the study a specialized dietician will monitor the patients. Blood samples will be collected to assess parameters of bacterial translocation, inflammation and immune activation. To assess compliances with diet, urine samples will be collected too, and stool samples to study changes in gut microbiota. All the samples will be collected at the beginning and 90 days after the inclusion in the study.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient ≥ 18 years of age;
  • To sign voluntary informed consent;
  • Male or female patients with a negative pregnancy test before inclusion in the study;
  • Proven HIV infection (with HIV-1 positive antibodies);
  • Patient should be on stable treatment with cART for at least 1 year
  • The mean of all CD4 measurements during the year prior to the initiation of cART should be equal to greater than 350 cells / mm3
  • The number of CD4 + at the time of recruitment must be equal to or greater than 500 cells / mm3;
  • HIV viral load should be undetectable at least 6 months prior to study inclusion, and less determinations (occasional blips above the undetectable level are allowed).

排除标准

  • Acquired Immunodeficiency Syndrome.
  • Active opportunistic diseases.
  • Patients coinfected with HCV or HBV
  • Coagulopathy
  • Renal insufficiency (creatinine> 1.5 mg / dL)
  • Pregnancy or breastfeeding
  • Inability to sign informed consent
  • Active opportunistic infections, or any active infection or cancer within 30 days prior to the screening visit;
  • Therapy with immunomodulatory agents, including cytokines (eg IL-2) and gammaglobulins or chemotherapy within 90 days prior to the screening visit;
  • Use of anticoagulant medication;
  • Use of any type of experimental medication during the 90 days prior to study entry;
  • Uncontrolled psychiatric disorder;
  • Patients with uncontrolled active autoimmune diseases;
  • Usual use of antibiotics

研究组 & 干预措施

mediterranean diet

Experimental

Patients do Mediterranean diet supplemented with 50 g / day of olive oil and 15g / day of nuts for three months

干预措施: mediterranean diet (Dietary Supplement)

Usual diet

No Intervention

Patients do usual diet for three months

结局指标

主要结局

Differences in levels of sCD14 at baseline and month 3 between groups

时间窗: 2 year

parameters of bacterial translocation

次要结局

  • Changes in expression of CD38, HLA DR in CD4 and CD8 T cells at baseline and month 3 between groups(2 years)
  • Changes in total and integrated DNA(2 years)
  • Changes in EndocAB and LBP levels at baseline and month 3 between groups.(2 year)
  • Changes in microbiota (fecal 16s rRNA) at baseline and month 3 between groups(2 years)
  • Changes in ultrasensitive PCR, TNF-alpha, IL-6 and Dimer-D at baseline and month 3 between groups(2 years)
  • Changes in lipids at baseline and month 3 between groups(2 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Felipe Garcia

DOCTOR

Hospital Clinic of Barcelona

研究点 (2)

Loading locations...

相似试验